Zhou Doctor طبيب استشاري

المستشفى الأول التابع لجامعة صن يات صن · Hepatobiliary Surgery · طبيب استشاري

A hepatobiliary surgeon and researcher at Sun Yat-sen University, holding a Doctor of Medicine degree. Specializes in liver cancer and minimally invasive surgery, with leadership roles in multiple medical associations. Published extensively on hepatocellular carcinoma biomarkers, signaling pathways, and treatment outcomes.

Primary treatment for benign and malignant diseases including primary liver cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, hepatic hemangioma, portal hypertension, upper gastrointestinal bleeding, and intrahepatic and extrahepatic bile duct stones. Specializes in radical cholecystectomy; radical hilar cholangiocarcinoma surgery; complex biliary stone surgery; radical resection of pancreatic head, body, and tail cancer; minimally invasive hepatectomy, cholecystectomy, and radi

Zhou Doctor
معلومات أساسية

About Dr. Zhou Doctor

المستشفى التابع له
المستشفى الأول التابع لجامعة صن يات صن
Title
طبيب استشاري
القسم
Hepatobiliary Surgery
عدد سنوات الخبرة
28 سنة (1998 حتى الآن)
**Education:** September 2001 - June 2004: Studied in the Department of Surgery at Sun Yat-sen University, awarded a Doctor of Medicine degree. **Work Experience:** July 2004 - Present: Attending Physician, Associate Chief Physician, Chief Physician in the Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University. **Professional Affiliations:** Vice Chairman of the Medical Equipment Working Committee, China Medical Education Association; Chairman of the Hepatobiliary and Pancreatic Minimally Invasive Specialized Committee, Guangdong Health Management Association; Leader of the Intraoperative Auxiliary Diagnosis Group, Hepatobiliary and Pancreatic Surgery Branch, Guangdong Medical Association; Deputy Leader of the Liver Cancer Study Group, Guangdong Medical Doctor Association. **Publications:** 1. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular Carcinoma. *AGING*. 2020. 2. Bioinformatics analysis on multiple Gene Expression Omnibus datasets of the hepatitis B virus infection and its response to the interferon-alpha therapy. *BMC Infectious Diseases*. 2020. 3. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness. *Molecular Carcinogenesis*. 2019. 4. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. *Journal of Experimental & Clinical Cancer Research*. 2019. 5. Comprehensive and combined omics analysis reveals factors of ischemia-reperfusion injury in liver transplantation. *Epigenomics*. 2019. 6. Targeting TF-AKT/EGFR Pathway Suppressed the Growth Of Hepatocellular Carcinoma. *Frontiers in Oncology*. 2019. 7. A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Sci Rep*. 2018. 8. Overexpression of signal sequence receptor γ (SSR3) predicts poor survival in patients with hepatocellular carcinoma. *Hum Pathol*. 2018. 9. Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells. *OncoImmunology*. 2016. 10. High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. *Biochemical and Biophysical Research Communications*. 2016. 11. Adult hepatic cavernous hemangioma with highly elevated α-fetoprotein: A case report and review of the literature. *Oncol Lett*. 2015. 12. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. *Med Oncol*. 2015. 13. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. *Oncol Rep*. 2013. 14. The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma. *BMC Cancer*. 2013. 15. Development of IGF Signaling Antibody Arrays for the Identification of Hepatocellular Carcinoma Biomarkers. *PLoS One*. 2012. 16. Identification of Max binding protein as a novel binding protein of Nck1 and characterization of its role in inhibiting human liver cancer SK-HEP-1 cells. *Chinese Medical Journal*. 2012. 17. Experimental study of single-pin puncture asymmetrical hydroablation using a conformational radiofrequency ablation electrode in ex vivo ox liver. *The British Journal of Radiology*. 2012. 18. Killing effects of different physical factors on extracorporeal HepG2 cells of human Hepatoma cell line. *Asian Pacific Journal of Cancer Prevention*. 2012. 19. Microwave Ablation Treatment of Liver Cancer with a 2,450-MHz Cooled-shaft Antenna: Pilot Study on Safety and Efficacy. *Asian Pacific Journal of Cancer Prevention*. 2012. 20. MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells. *Biochemical and Biophysical Research Communications*. 2012. 21. Prognostic Analysis for Treatment Modalities in Hepatocellular Carcinomas with Portal Vein Tumor Thrombi. *Asian Pacific Journal of Cancer Prevention*. 2011. **Monograph:** *Complications in Hepatobiliary, Pancreatic, and Splenic Surgery* **Other Major Achievements (e.g., Awards):** Selected as a candidate for the fifth batch of the "Thousand, Hundred, Ten Talent Project" of Guangdong Provincial Higher Education Institutions; Advanced Individual of Guangdong Health Management Association; Completed clinical training at the Hepatobiliary and Pancreatic Center, St. Vincent Hospital, USA. Principal investigator for 12 provincial and municipal research grants. Published over 60 papers in domestic and international core journals, including over 30 SCI-indexed papers as first author or corresponding author. Recipient of the Second Prize of Guangdong Provincial Medical Science and Technology Achievement Award.
وقت العيادة

Zhou Doctor جدول مواعيد عيادات المدير

الجدول الأسبوعي للعيادات، يشمل العيادات الخارجية / العيادات الخاصة / أيام العمليات. يُنصح بالحجز المسبق قبل 3-7 أيام

Clinic: المستشفى الأول التابع لجامعة صن يات صن · Hepatobiliary Surgery
On Duty
Off Duty
Period Morning
08:00-12:00
بعد الظهر
14:00-17:30
Evening
18:30-20:30
Mon
09:00 - 12:00
Off Duty Off Duty
Tue Off Duty Off Duty Off Duty
Wed Off Duty Off Duty Off Duty
Thu Off Duty Off Duty Off Duty
Fri Off Duty Off Duty Off Duty
Sat Off Duty Off Duty Off Duty
Sun Off Duty Off Duty Off Duty
Note: يُرجى الاعتماد على إعلان المستشفى في يوم الزيارة الفعلي، ويُنصح بالاتصال بخط Dovecure الساخن على مدار 24 ساعة 400-888-0000 للتأكيد قبل الحجز.
طبيب من نفس المستشفى

فريق الأورام المستشفى الأول التابع لجامعة صن يات صن

المزيد من أطباء الأورام الرئيسيين المتعاقدين مع مستشفانا

View all

احجز الآن مستشارًا خاصًا

فريق استشاري طبي خبير، بمتوسط خبرة مهنية تتجاوز 5 سنوات، وقد قدم خدمات الرعاية الطبية في الصين لأكثر من 1000 أسرة

احجز الآن مستشارًا خاصًا

فريق استشاري طبي خبير، بمتوسط خبرة مهنية تتجاوز 5 سنوات، وقد قدم خدمات الرعاية الطبية في الصين لأكثر من 1000 أسرة

استشر الآن
استشارة على مدار 7*24 ساعة 400-888-0000
استشارة عبر البريد الإلكتروني cure@dovecure.com
استشارة عبر واتساب WeChat QR Code WeChat QR Code
السلة
عربة التسوق الخاصة بك فارغة
واصل التسوق
{{ item.sku_code }} - {{ item.variant_label }} {{ item.item_type_label }}
{{ item.price_format }}
{{ item.subtotal_format }}
الإجمالي {{ totalAmount }}
الدفع الآن أدخل عربة التسوق
استشارة